A team of Vanderbilt and Nashville VA researchers, led by Adriana Hung, M.D., MPH, has been awarded a grant from the U.S. Department of Veterans Affairs to use the Million Veteran Program (MVP) data to conduct diabetes research.

Vanderbilt University researchers have come closer to solving a mystery that has puzzled scientists for more than a century: after the loss of one kidney, what causes the growth of the remaining kidney to take up the slack?

TGF-beta signaling in the kidney was thought to be a target for reducing renal fibrosis, but Vanderbilt researchers report that fibrosis still occurs in the absence of TGF-beta signaling.

Diabetic nephropathy, or kidney disease caused by diabetes, is a major source of morbidity and mortality. In the United States, more than 30 percent of patients receiving either dialytic therapy or renal transplantation have end stage renal disease as a result of diabetic nephropathy.

Vanderbilt Stallworth Rehabilitation Hospital (VSRH) is now offering hemodialysis for its patients, eliminating the need to transport them off site for treatment.

Researchers in Vanderbilt’s Division of Nephrology conducted a Phase 3 clinical trial to test the safety and efficacy of a new drug to treat patients with end-stage renal disease.

Vanderbilt University Medical Center, committed to providing multiple options to patients who have kidney disease, recently began offering nocturnal in-center hemodialysis, which allows patients to receive treatment at night while they sleep.